期刊文献+

SMAR1和CYCLIND1蛋白在大肠癌中的表达及临床意义 被引量:1

Expression and Clinical Significance of SMAR1 and CYCLIND1 in Colorectal Carcinoma
下载PDF
导出
摘要 目的检测SMAR1和CYCLIND1蛋白在大肠癌中的表达及临床意义。方法以大肠癌旁正常组织30例为对照,免疫组化检测128例大肠癌组织SMAR1、CYCLIND1蛋白的表达,分析SMAR1、CYCLIND1表达与临床病理因素的关系及其对大肠癌预后的影响。结果 SMAR1、CYCLIND1蛋白在大肠癌组织和正常组织的阳性表达率分别为44.5%vs76.6%和61.7%vs13.3%,差异均具有统计学意义;SMAR1蛋白的表达与大肠癌Dukes分期、浸润深度、淋巴结转移及分化类型相关(P<0.05);SMAR1蛋白表达与CYCLIND1的表达呈负相关(r=-0.75,P<0.05);SMAR1蛋白低表达、CYCLIND1蛋白高表达的大肠癌患者预后较差。结论 SMAR1、CYCLIND1蛋白的表达与大肠癌的临床病理学特征密切相关,可能参与了大肠癌的侵袭和转移,并对大肠癌的预后产生影响。 Objective To explore the expression of SMAR1 and CYCLIND1 proteins in colorectal carcinoma and their functions in the prognosis of colorectal carcinoma( CRC ). Methods We measured SMAR1 and CYCLIND1 expression in 128 specimens of CRC and 30 specimens of normal colorectal tissue by immunohistochemistry,and analyzed the relationship between these protein expression and the clinicopathological parameters,and explored the prognosis in CRC. Results The positive rates of expression of SMAR1 and CYCLIND1 in CRC specimens and normal co]orectal tissue were 44.5% vs 76.6% and 61.7% vs 13.3% ,with a significant difference. The expression of SMAR1 protein was correlated with Dukes stage, infiltration degree, lymphatic metastasis and the degree of cancer differentiation(P〈0.05) ;The expression of SMAR1 protein was negatively correlated with tha! of C YCLINDI protein(r=-0.75 ,P〈0.05 ). The low expression of SMAR1 and high expression of CYCLIND1 protein in CRC had poor prognosis. Conclusion SMAR1 and CYCLIND1 expression is correlated with the clinical path physiological characteristics in CRC,and the proteins might be correlated with the local invasion,distant metastasis and the prognosis of CRC.
出处 《中国现代医生》 2010年第16期4-6,F0003,共4页 China Modern Doctor
关键词 大肠癌 SMAR1 CYCLIND1 免疫组化 预后 Colorectal carcinoma SMAR1 CYCLIND 1 Immunohistochcmistry Prognosis
  • 相关文献

参考文献1

共引文献22

同被引文献27

  • 1Nakka KK, Chattopadhyay S. Modulation of chromatin by MARs and MAR binding oncogenic transcription factor SMARI[J]. Mol Cell Biochem, 2010, 336 (1-2): 75-84.
  • 2Chattopadhyay S, Pavithra L. MARs and MARBPs: key modulators of gene regulation and disease manifestation [J]. Subcell Biochem, 2007, 41: 213-230.
  • 3Kaul-Ghanekar R, Majumdar S, Jalota A, et al. Abnormal V (D)J recombination of T cell receptor beta locus in SMAR1 transgenic mice[J]. J Biol Chem, 2005, 280 (10): 9450-9459.
  • 4Chattopadhyay S, Kaul R, Charest A, et al. SMAR1, a novel, alternatively spliced gene product, binds the Scaffold/Matrix-associated region at the T cell receptor beta locus[J]. Genomics, 2000, 68 (1): 93-96.
  • 5Malonia SK, Sinha S, Lakshminarasimhan P, et al. Gene regulation by SMARI: Role in cellular homeostasis and cancer[J]. Biochim Biophys Acta, 2011, 1815 (1): 1-12.
  • 6Gong G, DeVries S, Chew KL, et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomie hybridization[J]. Clin Cancer Res, 2001, 7 (8): 2410-2414.
  • 7Miller B J, Wang D, Krahe R, et al. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for muhiple tumor suppressors and identifies novel candidate regions[J]. Am J Hum Genet, 2003, 73 (4): 748-767.
  • 8Singh K, Mogare D, Giridharagopalan RO, et al. p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell migration and invasion[J]. PLoS One, 2007, 2 (7): e660.
  • 9Kaul R, Mukherjee S, Ahmed F, et al. Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice[J]. Int J Cancer, 2003, 103 (5): 606-615.
  • 10Jalota-Badhwar A, Kaul-Ghanekar R, Mogare D, et al. SMARl-derived P44 peptide retains its tumor suppressor function through modulation of p53[J]. J Biol Chem, 2007, 282 (13): 9902-9913.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部